

**April 2010**

Volume 15 · Numbers 7/8

pp. 253–324

**Cover Story**

This special issue of Drug Discovery Today deals with the topic of age-related sensory impairment. The issue has been produced in association with and with the help of the RNID and Fight-for-Sight. The issue covers issues in research into conditions affecting sight, including delivery of anti-angiogenic molecular therapies for retinal disease and treatment strategies for age-related optic nerve disease: advances in glaucoma research. We also cover the latest research in hearing disorders, which include using the zebrafish lateral line to screen for drugs that prevent and cause hearing loss, pharmacological approaches to the treatment of tinnitus and cochlear implantation: an opportunity for drug development. We hope that pulling together reviews on some of the cutting edge research going into treatments for sensory impairment will prove interesting and stimulating to the expert and interested reader alike.

DRUG DISCOVERY TODAY

REVIEWS

POST SCREEN

- 265 Drug screening for hearing loss: Using the zebrafish lateral line to screen for drugs that prevent and cause hearing loss**
Henry C. Ou, Felipe Santos, David W. Raible, Julian A. Simon and Edwin W. Rubel
- 272 Delivery of anti-angiogenic molecular therapies for retinal disease**
Owen A. Anderson, James W.B. Bainbridge and David T. Shima
- 283 Stem cells and cell lines from the human auditory organ: applications, hurdles and bottlenecks in the development of regenerative therapies for deafness**
Marcelo N. Rivolta
- 287 Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies**
A.H. Dahlmann-Noor, S. Vijay, G. Astrid Limb and P.T. Khaw
- 300 Pharmacological approaches to the treatment of tinnitus**
Ana B. Elgoyhen and Berthold Langguth
- 306 Stem cell therapies for ocular surface disease**
Sajjad Ahmad, Sai Kolli, Majlinda Lako, Francisco Figueiredo and Julie T. Daniels
- 314 Cochlear implantation: an opportunity for drug development**
Hinrich Staecker, Claude Jolly and Carolyn Garnham

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Assistant Editor:** Kirsty Strawbridge**Content Development Manager:** Joanna Aldred**Journal Manager:** Basil Nyaku**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jürgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong, Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Pfizer Global Biologics, St. Louis, USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica, China***Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd, USA***Janice Reichert** *Tufts Center for the Study of Drug Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute, USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston, USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

EDITORIAL

253 Hearing loss and tinnitus – the hidden healthcare time bomb*Denise R. Goldman and Ralph Holme***256 New therapies to treat sight loss in an ageing population***Michele L. Acton and Dolores M. Conroy*

PERSPECTIVE

FEATURE**260 The future of discovery chemistry: *quo vadis?* Academic to industrial – the maturation of medicinal chemistry to chemical biology***Torsten Hoffmann and Cheryl Bishop*

MONITOR

322 New agents for the treatment of leukemia: discovery of DMAPT (LC-1)*Kevin Peese***323 DIARY**